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Several cancer drugs intercept the ErbB family receptors EGFR (ErbB-1) and HER2 (ErbB-2). However, the
therapeutic value of targeting ErbB-3 has been less clear. A report in this issue of Cancer Cell by Sheng
et al. renews hopes that intercepting ErbB-3-mediated autocrine loops bears potential for treatment of
ovarian cancer.Animal and other experimental models
have provided ample evidence in support
of a major role of the epidermal growth
factor (EGF) receptor (EGFR) family
(HER1, -2, -3, and -4, a.k.a. ErbB1, -2,
-3, and -4) in differentiation of the epithelial
lineage into diverse derivatives, such as
the simple columnar epithelium deco-
rating the outer surface of the ovary.
A broad family of EGF-like growth factors
that selectively bind discrete members of
the EGFR family are secreted by stromal
cells that underline the epithelium. These
growth factors bind ErbB receptors
expressed at the basolateral aspect of
epithelial cells to enhance the tyrosine
phosphorylation of these receptors and
their subsequent coupling to an inositol
lipid kinase (PI3K) and activation of the
downstream AKT kinase pathway. The ac-
tivated AKT pathway, together with the
RAS-MAPK pathway, enables cell survival
and proliferation. While studying tumor
viruses in the late 1970s, George Todaro
and Michael Sporn noted a general, virally
induced secretion of growth factors,
which enables repeated autostimulation
of infected cells, a phenomenon they
coined ‘‘autocrine stimulation’’ (Sporn
and Todaro, 1980). Later studies docu-
mented countless examples of autocrine
loops in human cancer (Burgess, 2008).
However, whether autocrine loops can
actively drive tumor initiation and progres-
sion, in analogy to driver mutations af-
fecting oncogenes and tumor suppressor
genes, remains an open issue that bears
relevance for cancer treatment: intercept-
ing growth factors using antibodies,
soluble decoy receptors, and other means
represents a validated approach for
cancer therapy.Qing Sheng and colleagues present, in
this issue of Cancer Cell, compelling
evidence identifying an essential autocrine
loop, amenable for therapeutic interven-
tion in ovarian cancer, the deadliest form
of all gynecological cancers (Sheng et al.,
2010). As a springboard, their study
screened a library of short hairpin RNAs
(shRNAs) targeting 89 human tyrosine
kinases, a family of enzymes frequently
involved in cancer due to gain-of-function
mutations or gene amplification. On intro-
duction into SKOV3 ovarian cancer cells,
they observed reproducible inhibition of
cell proliferation by shRNAs targeting
EphA4, KDR, and ErbB-3. ErbB-3 not
only scored the highest but also repre-
sented an interesting ‘‘catch’’ of the func-
tional fishing expedition: unlike KDR and
EphA4, it belongs to an enigmatic sub-
group of tyrosine kinase family members
called pseudokinases because their cata-
lytic function is inactive. Aberrant expres-
sion or mutation of ErbB-3 in tumors,
including ovarian cancer, is extremely
rare, unlike the other three ErbB family
members that are often mutated or over-
expressed, e.g., ErbB-4 in melanoma
(Prickett et al., 2009), ErbB-1/EGFR in
lung cancer, and ErbB-2/HER2 in breast,
ovarian, and gastric cancer (Slamon
et al., 1987) (see Figure 1). To complicate
the matter, the extracellular domain of
ErbB-3 binds several growth factors,
called neuregulins (NRGs), and upon
transphosphorylation by several other
tyrosine kinases, such as ErbB-2/HER2,
the cytoplasmic domain of ErbB-3 ro-
bustly recruits PI3K.
SKOV3 cells carry complex genetic
alterations, which include amplification
of ErbB2, mutation of PIK3CA, deletionCancer Cell 1of CDKN2A, and mutation of TP53, and
are near tetraploid, therefore, likely repre-
sent only a small subset of ovarian can-
cers. Candidates from the original screen
using SKOV3 cells were validated using
OVCAR8 cells, which have a mutation of
TP53 but do not have other genetic aber-
rations present in SKOV3 cells mentioned
above. It is thus likely that additional tyro-
sine kinase screens in other genetic back-
grounds relevant to ovarian cancer would
identify additional dependencies and po-
tential therapeutic targets.
Using OVCAR8, which expresses a con-
stitutively phosphorylated form of ErbB-3,
Sheng and collaborators applied an
exhaustive set of tests that validated the
ability of ErbB-3 to support cellular prolif-
eration. Intriguingly, despite the role for
the PI3K pathway as the main target for
ErbB-3 in maintaining cell viability, they
did not find evidence for an effect of
knockdown of ErbB-3 on cellular viability
in vitro. Next, they addressed the molec-
ular basis of constitutive ErbB-3 phos-
phorylation in OVCAR8 cells. After ex-
cluding activation due to mutations or
interactions with other ErbB family mem-
bers, they examined a potential NRG
autocrine loop. Indeed, PCR and immuno-
blotting detected NRG1 synthesis and
secretion, and siRNAs specific to NRG1
(siNRG1) reduced ErbB-3 phosphoryla-
tion, as well as proliferation of OVCAR8
cells in vitro. Importantly, proliferation of
ovarian cancer cells that express neither
NRG1 nor a phosphorylated form of
ErbB-3 was not affected by siNRG1, sug-
gesting both an important mechanism
and a potential biomarker for selection of
patients likely to benefit from interruption
of the NRG1/ErbB-3 autocrine loop.7, March 16, 2010 ª2010 Elsevier Inc. 217
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Figure 1. Functional and Pathological Differences between ErbB-1 and ErbB-3
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PreviewsSeveral monoclonal antibodies able to
inhibit EGF binding to EGFR/ErbB-1 have
been approved for treatment of human
cancers (e.g., Bonner et al., 2006). Like-
wise, although no growth factor directly
binds with HER2/ErbB-2, trastuzumb, a
monoclonal antibody that recognizes the
extracellular domain of this receptor, has
improved outcomes for breast cancer
patients. A similar, previously developed
human monoclonal antibody able to
displace NRG1 from its binding site on
ErbB-3 (Schoeberl et al., 2009), was
utilized by Sheng et al. to test the rele-
vance of the autocrine loop they discov-
ered to treatment of ovarian tumors.
Consistent with the ability of the anti-
ErbB-3 antibody to reduce tyrosine phos-
phorylation of ErbB-3 in cultured OVCAR8
cells, when injected into animals bearing
small OVCAR8 xenografts, the antibody
decreased, but did not abrogate, tumori-
genic growth. In addition, inducible
knockdown of ErbB-3 expression in a
similar xenograft model lent support to
their hypothesis that the NRG1/ErbB-3
autocrine loop drives growth of ovarian
tumors in vivo. Indeed, one of the induc-
ible shRNA constructs decreased tumor
volume in vivo, compatible with the possi-
bility that complete interruption of the
NRG1/ErbB-3 autocrine loop, which only
decreased cell growth in vitro, might result
in death of ovarian cancer cells in the218 Cancer Cell 17, March 16, 2010 ª2010 Ein vivo environment. This suggests that
targeting ErbB-3 may demonstrate ac-
tivity as a single agent; however, as with
many other targeted therapies, the opti-
mal efficacy is likely to be realized through
combinatorial therapy with the potential
that blocking NRG1 binding to ErbB-3
will sensitize ovarian tumors to the toxic
effects of platinum-based or other chemo-
therapy regimens.
Beyond offering a novel target for
therapy, as well as a potential treatment
approach to ovarian cancer, which re-
mains a devastating disease, the authors
proposean attractive biomarker for patient
selection, namely the level of ErbB-3 phos-
phorylation in tumors. Moreover, their
analyses of cell lines and 20 fresh prepara-
tions of cells isolated frompatients’ ascites
fluid,estimate thatapproximatelya quarter
of advanced ovarian cancer patients may
present an operational NRG1/ErbB-3 au-
tocrine loop, and hence benefit from treat-
ment with anti-ErbB-3 targeted agents.
Three ErbB-3 targeted approaches are
currently in clinical trials (clinicaltrials.
gov): AMG888 (Amgen) and MM-121
(Merrimack Pharmaceuticals) are anti-
bodies that prevent binding of ligands to
ErbB-3 and may modestly downregulate
receptor expression or membrane locali-
zation. MM-111 (Merrimack Pharmaceuti-
cals), a bispecific antibody designed to
target both ErbB-2 (HER2) and ErbB-3,lsevier Inc.is in trials for tumors overexpressing
ErbB-2. However, none of these trials
use the presence phosphorylated ErbB-
3 or the presence of an HRG1 ErbB-3
autocrine loop to select patients likely to
benefit and, hence, may miss the most
appropriate patient population to deter-
mine the utility of ErbB-3-targeted ther-
apy. A number of preclinical studies
targeting ErbB-3 are underway. One of
these, EZN-3920 (Enzon Pharmaceuti-
cals), a high-affinity, locked nucleic acid
(LNA) antisense molecule that silences
ErbB-3 and demonstrates efficacy in
animal models, is nearing clinical testing.
In summary, together with recent studies
identifying the kinase-dead receptor,
ErbB-3, as the culprit behind patient
resistance to kinase inhibitors (Engelman
et al., 2007; Sergina et al., 2007), the
new discovery of an ErbB-3-mediated
addiction of a subset of ovarian cancers
to growth factors zooms a major clinical
spotlight on this rather neglected brother
of an oncogenic receptor family.
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